How accurate is multiparametric MR imaging in evaluation of prostate cancer volume?

Radiology

Volumn 275, Issue 1, 2015, Pages 144-154

  Bratan, Flavie ^a,b,c,d   Melodelima, Christelle ^e,f   Souchon, Rémi ^d   Dinh, Au Hoang ^d   Mège Lechevallier, Florence ^a   Crouzet, Sébastien ^a,b,c,d   Colombel, Marc ^a,b,c   Gelet, Albert ^a,d   Rouvière, Olivier ^a,b,c,d  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d LABTAU   (France)

^e UNIVERSITÉ JOSEPH FOURIER   (France)

^f CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER TISSUE; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGING SYSTEM; INFORMED CONSENT; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; STANDARD; TUMOR VOLUME; BLOOD; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC ERROR; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA;

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGED; DIAGNOSTIC ERRORS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84926506773     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14140524     Document Type: Article

References (55)

1. Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection-histopathologic correlation. Radiology 2010;255(1):89-99.
2. Vargas HA, Akin O, Shukla-Dave A, et al. Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. Radiology 2012;265(2):478-487.
3. Selnæs KM, Heerschap A, Jensen LR, et al. Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology. Invest Radiol 2012;47(11):624-633.
4. Isebaert S, De Keyzer F, Haustermans K, et al. Evaluation of semi-quantitative dynamic contrast-enhanced MRI parameters for prostate cancer in correlation to whole-mount histopathology. Eur J Radiol 2012;81(3):e217-e222.
5. Bratan F, Niaf E, Melodelima C, et al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol 2013;23(7):2019-2029.
6. Ahmed HU, Kirkham A, Arya M, et al. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 2009;6(4):197-206.
7. Moore CM, Robertson NL, Arsanious N, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 2013;63(1):125-140.
8. Sciarra A, Barentsz J, Bjartell A, et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 2011;59(6):962-977.
9. Puech P, Rouvière O, Renard-Penna R, et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy-prospective multicenter study. Radiology 2013;268(2):461-469.
10. Cheikh AB, Girouin N, Colombel M, et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol 2009;19(3):770-778.
11. Park BK, Park JW, Park SY, et al. Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostatespecific antigen and no previous biopsy. AJR Am J Roentgenol 2011;197(5):W876-W881.
12. Vourganti S, Rastinehad A, Yerram NK, et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol 2012;188(6):2152-2157.
13. Hoeks CM, Schouten MG, Bomers JG, et al. Three-tesla magnetic resonance-guided prostate biopsy in men with increased prostatespecific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol 2012;62(5):902-909.
14. Hambrock T, Hoeks C, Hulsbergen-Van De Kaa C, et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 2012;61(1):177-184.
15. Sonn GA, Natarajan S, Margolis DJ, et al. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol 2013;189(1):86-91.
16. Delongchamps NB, Peyromaure M, Schull A, et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. J Urol 2013;189(2):493-499.
17. Kuru TH, Roethke MC, Seidenader J, et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. J Urol 2013;190(4):1380-1386.
18. Kasivisvanathan V, Dufour R, Moore CM, et al. Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol 2013;189(3):860-866.
19. Habchi H, Bratan F, Paye A, et al. Value of prostate multiparametric magnetic resonance imaging for predicting biopsy results in first or repeat biopsy. Clin Radiol 2014;69(3):e120-e128.
20. Siddiqui MM, Rais-Bahrami S, Truong H, et al. Magnetic resonance imaging/ultrasoundfusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol 2013;64(5):713-719.
21. Van As NJ, De Souza NM, Riches SF, et al. A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol 2009;56(6):981-987.
22. Turkbey B, Mani H, Aras O, et al. Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology 2013;268(1):144-152.
23. Vargas HA, Akin O, Afaq A, et al. Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol 2012;188(5):1732-1738.
24. Park BH, Jeon HG, Choo SH, et al. Role of multiparametric 3.0-tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance. BJU Int 2014;113(6):864-870.
25. Rouvière O, Gelet A, Crouzet S, Chapelon JY. Prostate focused ultrasound focal therapy: imaging for the future. Nat Rev Clin Oncol 2012;9(12):721-727.
26. Coakley FV, Kurhanewicz J, Lu Y, et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002;223(1):91-97.
27. Nakashima J, Tanimoto A, Imai Y, et al. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology 2004;64(1):101-105.
28. Mazaheri Y, Hricak H, Fine SW, et al. Prostate tumor volume measurement with combined T2-weighted imaging and diffusionweighted MR: correlation with pathologic tumor volume. Radiology 2009;252(2):449-457.
29. Turkbey B, Mani H, Aras O, et al. Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol 2012;188(4):1157-1163.
30. Knoedler JJ, Karnes RJ, Thompson RH, Rangel LJ, Bergstralh EJ, Boorjian SA. The association of tumor volume with mortality following radical prostatectomy. Prostate Cancer Prostatic Dis 2014;17(2):144-148.
31. Akin O, Sala E, Moskowitz CS, et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 2006;239(3):784-792.
32. Lemaitre L, Puech P, Poncelet E, et al. Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur Radiol 2009;19(2):470-480.
33. Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2010;257(3):715-723.
34. Chesnais AL, Niaf E, Bratan F, et al. Differentiation of transitional zone prostate cancer from benign hyperplasia nodules: evaluation of discriminant criteria at multiparametric MRI. Clin Radiol 2013;68(6):e323-e330.
35. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011;59(4):477-494.
36. Samaratunga H, Montironi R, True L, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Mod Pathol 2011;24(1):6-15.
37. Cornud F, Khoury G, Bouazza N, et al. Tumor target volume for focal therapy of prostate cancer-does multiparametric magnetic resonance imaging allow for a reliable estimation? J Urol 2014;191(5):1272-1279.
38. Hughes C, Rouvière O, Mege-Lechevallier F, Souchon R, Prost R. Robust alignment of prostate histology slices with quantified accuracy. IEEE Trans Biomed Eng 2013;60(2):281-291.
39. Ward AD, Crukley C, McKenzie CA, et al. Prostate: registration of digital histopathologic images to in vivo MR images acquired by using endorectal receive coil. Radiology 2012;263(3):856-864.
40. Orczyk C, Rusinek H, Rosenkrantz AB, et al. Preliminary experience with a novel method of three-dimensional co-registration of prostate cancer digital histology and in vivo multiparametric MRI. Clin Radiol 2013;68(12):e652-e658.
41. Lindner U, Trachtenberg J, Lawrentschuk N. Focal therapy in prostate cancer: modalities, findings and future considerations. Nat Rev Urol 2010;7(10):562-571.
42. Ahmed HU, Freeman A, Kirkham A, et al. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol 2011;185(4):1246-1254.
43. Ahmed HU, Hindley RG, Dickinson L, et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 2012;13(6):622-632.
44. Rosenkrantz AB, Kim S, Lim RP, et al. Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales. Radiology 2013;269(2):482-492.
45. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012;22(4):746-757.
46. Turkbey B, Merino MJ, Gallardo EC, et al. Comparison of endorectal coil and nonendorectal coil T2W and diffusionweighted MRI at 3 tesla for localizing prostate cancer: correlation with whole-mount histopathology. J Magn Reson Imaging 2014;39(6):1443-1448.
47. Heijmink SW, Scheenen TW, Van Lin EN, et al. Changes in prostate shape and volume and their implications for radiotherapy after introduction of endorectal balloon as determined by MRI at 3T. Int J Radiat Oncol Biol Phys 2009;73(5):1446-1453.
48. Langer DL, Van Der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers. Radiology 2008;249(3):900-908.
49. Rosenkrantz AB, Mendrinos S, Babb JS, Taneja SS. Prostate cancer foci detected on multiparametric magnetic resonance imaging are histologically distinct from those not detected. J Urol 2012;187(6):2032-2038.
50. Puech P, Sufana-Iancu A, Renard B, Lemaitre L. Prostate MRI: can we do without DCE sequences in 2013? Diagn Interv Imaging 2013;94(12):1299-1311.
51. Dhingsa R, Qayyum A, Coakley FV, et al. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology 2004;230(1):215-220.
52. Hom JJ, Coakley FV, Simko JP, et al. Prostate cancer: endorectal MR imaging and MR spectroscopic imaging-distinction of true-positive results from chance-detected lesions. Radiology 2006;238(1):192-199.
53. Hom JJ, Coakley FV, Simko JP, et al. Highgrade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features-initial experience. Radiology 2007;242(2):483-489.
54. Schned AR, Wheeler KJ, Hodorowski CA, et al. Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol 1996;20(12):1501-1506.
55. Stamey TA, McNeal JE, Freiha FS, Redwine E. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 1988;139(6):1235-1241.